



Alexandra Snyder, Esq.  
*Chief Executive Officer*  
Catherine W. Short, Esq.  
*Chief Legal Officer*  
Mary Riley  
*Chief Operation/Finance Officer*  
Allison K. Aranda, Esq.  
*Senior Staff Counsel*

**Board of Directors**

John R. Streett, Esq.  
*Chairman*  
Gellert Dornay  
Patrick Laurence, Esq.  
John Madigan, JD  
Maria McCarthy, Esq.  
Christopher Schweickert, Esq.  
David Shaneyfelt, Esq.  
Colette Wilson, Esq.

**Advisory Board**

The Hon. Steve Baldwin  
*San Diego, California*  
The Rev. Joseph D. Fessio, SJ  
*San Francisco, California*  
Robert P. George  
*Princeton University*  
The Hon. Ray Haynes  
*Riverside, California*  
James Hirsen, Esq.  
*Riverside, California*  
The Hon. Howard Kaloogian  
*Los Angeles, California*  
David Llewellyn, Esq.  
*Sacramento, California*  
Anne J. O'Connor, Esq.  
*New Jersey*  
Ben Stein, Esq.  
*West Hollywood, California*  
Andrew Zepeda, Esq.  
*Beverly Hills, California*

**Northern California**  
(Administration)  
P.O. Box 2105  
Napa, California 94558  
(707) 224-6675

**Southern California**  
P.O. Box 1313  
Ojai, California 93024  
(805) 640-1940

**LifeLegal.org**

Alexandra Snyder, Esq.  
Life Legal Defense Foundation  
P.O. Box 2105  
Napa, CA 94558  
[www.lifelegal.org](http://www.lifelegal.org)  
[info@lifelegal.org](mailto:info@lifelegal.org)

**April 30, 2025**

Dr. Marty Makary, Commissioner  
U.S. Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002

**RE: Urgent Request to Reevaluate FDA Policy on Mifepristone**

Dear Commissioner Makary:

On behalf of Life Legal, a national public interest law firm committed to protecting the rights of vulnerable human beings, we write to express our deep concern over the FDA's continued endorsement of the abortion drug Mifepristone under weakened safety protocols.

A newly released study from the *Ethics and Public Policy Center* confirms what many in the medical and legal communities have long suspected: **abortion pills are not as safe as the FDA claims.** The data reveal a significant rise in complications, including life-threatening hemorrhaging and emergency interventions—particularly since the FDA lifted longstanding safeguards such as in-person dispensing, physician oversight, and ultrasound verification.

Despite growing evidence of harm from Mifepristone, the FDA has refused to revisit its abortion drug policy. Just last week, you publicly stated that the agency has no intention of revising its stance on abortion pills, unless presented with “new data” suggesting a safety risk. That data now exists—and it demands immediate action.

We therefore urge the FDA to:

- 1. Suspend approval of Mifepristone** pending a full safety review; or at minimum,
- 2. Reinstate essential safety measures**, including:

- Mandatory in-person visits (at least three)
- Physician-only prescribing and supervision
- Ultrasounds to determine gestational age and rule out ectopic pregnancy
- On-site drug administration, not home use
- Required access to emergency care
- Reporting of all serious adverse events
- A return to the 7-week gestational limit

The FDA's mission is to protect public health based on scientific evidence—not political pressure. Women's lives and well-being are being placed at grave risk by the current lax regulatory framework surrounding chemical abortion.

We urge you to fulfill your duty and take immediate steps to ensure that abortion drugs are subject to the same rigorous oversight required for all high-risk medications.

Thank you for your attention to this matter. We would welcome the opportunity to speak further with you or your staff about these concerns.

Sincerely,



Alexandra Snyder  
CEO, Life Legal Defense Foundation  
Alexandra@LifeLegal.org

